Your browser is no longer supported. Please, upgrade your browser.
SLDB [NASD]
Solid Biosciences Inc.
Index- P/E- EPS (ttm)-0.85 Insider Own12.73% Shs Outstand112.31M Perf Week-9.87%
Market Cap189.21M Forward P/E- EPS next Y-0.83 Insider Trans0.00% Shs Float82.84M Perf Month-28.09%
Income-74.90M PEG- EPS next Q-0.22 Inst Own70.90% Short Float7.97% Perf Quarter-39.64%
Sales10.50M P/S18.02 EPS this Y41.60% Inst Trans-3.68% Short Ratio4.25 Perf Half Y-56.33%
Book/sh1.99 P/B0.85 EPS next Y-13.00% ROA-30.90% Target Price9.58 Perf Year-51.71%
Cash/sh2.05 P/C0.82 EPS next 5Y- ROE-35.40% 52W Range1.68 - 11.58 Perf YTD-77.70%
Dividend- P/FCF- EPS past 5Y-53.40% ROI- 52W High-85.41% Beta0.88
Dividend %- Quick Ratio10.60 Sales past 5Y- Gross Margin- 52W Low0.60% ATR0.14
Employees70 Current Ratio10.60 Sales Q/Q- Oper. Margin- RSI (14)33.38 Volatility7.86% 7.15%
OptionableYes Debt/Eq0.00 EPS Q/Q63.60% Profit Margin- Rel Volume1.91 Prev Close1.77
ShortableYes LT Debt/Eq0.00 EarningsNov 04 AMC Payout- Avg Volume1.55M Price1.69
Recom2.60 SMA20-17.71% SMA50-22.57% SMA200-56.47% Volume2,967,771 Change-4.52%
Jul-12-21Initiated Piper Sandler Neutral $6
May-27-21Initiated Jefferies Buy $7
Mar-16-21Upgrade SVB Leerink Mkt Perform → Outperform $3 → $15
Mar-09-21Initiated Barclays Overweight $13
Jan-08-21Upgrade Credit Suisse Underperform → Neutral $2 → $7
Jul-28-20Downgrade SVB Leerink Outperform → Mkt Perform
May-07-20Downgrade Evercore ISI Outperform → In-line
Oct-11-19Initiated Evercore ISI Outperform $22
Aug-29-19Downgrade Citigroup Neutral → Sell $6
Aug-19-19Upgrade SVB Leerink Mkt Perform → Outperform $8 → $15
Aug-16-19Upgrade Chardan Capital Markets Neutral → Buy $7.50 → $10
May-14-19Downgrade Goldman Neutral → Sell $5 → $4
May-14-19Downgrade Credit Suisse Neutral → Underperform $7 → $6
Feb-08-19Upgrade Citigroup Sell → Neutral $8
Feb-08-19Downgrade SVB Leerink Outperform → Mkt Perform
Nov-06-18Initiated Citigroup Sell
Sep-06-18Initiated Credit Suisse Neutral $38
Nov-23-21 11:08AM  
Nov-18-21 11:21AM  
Nov-03-21 08:35AM  
07:05AM  
Nov-02-21 07:30AM  
Oct-21-21 08:00AM  
Oct-04-21 08:00AM  
Oct-01-21 04:00PM  
Sep-29-21 07:00AM  
Sep-23-21 10:14AM  
06:00AM  
Sep-22-21 08:32AM  
Sep-21-21 12:07PM  
Sep-20-21 04:05PM  
04:01PM  
Aug-24-21 08:00AM  
Aug-19-21 08:05AM  
08:00AM  
Aug-16-21 06:45PM  
04:11PM  
Jul-19-21 12:16PM  
Jul-02-21 08:00AM  
Jul-01-21 08:00AM  
Jun-22-21 08:05AM  
Jun-07-21 07:35AM  
07:30AM  
May-26-21 07:30AM  
May-25-21 04:03PM  
May-14-21 08:00PM  
07:30AM  
06:45AM  
May-11-21 08:00AM  
May-04-21 08:00AM  
Apr-20-21 07:30AM  
Apr-13-21 06:56AM  
Apr-12-21 07:30AM  
Mar-26-21 05:02PM  
Mar-25-21 07:30AM  
Mar-24-21 08:50AM  
Mar-23-21 04:22PM  
Mar-18-21 09:14PM  
Mar-17-21 04:20PM  
08:32AM  
06:35AM  
Mar-16-21 11:44AM  
11:16AM  
08:17AM  
08:07AM  
Mar-15-21 04:15PM  
02:30PM  
Mar-04-21 07:35AM  
07:30AM  
Feb-24-21 04:24PM  
Feb-17-21 07:30AM  
Jan-22-21 07:00AM  
Jan-08-21 07:23PM  
04:30PM  
11:57AM  
Jan-06-21 07:30AM  
Jan-04-21 09:34AM  
Dec-24-20 04:00PM  
Dec-11-20 02:36PM  
07:30AM  
Dec-09-20 07:51AM  
Dec-07-20 09:42AM  
Nov-05-20 07:00AM  
Nov-03-20 07:30AM  
Oct-28-20 03:03PM  
Oct-23-20 08:00AM  
Oct-09-20 08:54AM  
Oct-02-20 02:56PM  
07:30AM  
Oct-01-20 02:56PM  
11:02AM  
07:30AM  
Sep-11-20 02:45PM  
Sep-10-20 10:19AM  
Aug-21-20 03:00PM  
Jul-29-20 09:12PM  
Jul-28-20 12:50PM  
Jul-27-20 12:16PM  
Jul-24-20 05:50PM  
Jul-05-20 05:27PM  
Jun-18-20 07:00AM  
Jun-12-20 06:45AM  
May-29-20 08:35AM  
May-22-20 07:00AM  
May-14-20 07:00AM  
May-13-20 09:49AM  
May-11-20 03:03AM  
May-09-20 01:48PM  
May-07-20 07:22AM  
Apr-16-20 07:00AM  
Mar-12-20 07:00AM  
Jan-31-20 05:00AM  
Jan-22-20 11:48AM  
Jan-10-20 10:08AM  
Jan-09-20 08:00AM  
Dec-23-19 10:11AM  
Dec-19-19 06:08PM  
Solid Biosciences Inc., a life science company, engages in developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a complementary disease modifying program that identifies and develops a monoclonal antibody intended to reduce fibrosis and inflammation by targeting and stabilizing the LTBP4 protein. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits. Solid Biosciences Inc. has strategic collaboration with Ultragenyx to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PERCEPTIVE ADVISORS LLCDirectorMar 23Buy5.752,608,69514,999,99613,412,552Mar 23 05:19 PM
RA CAPITAL MANAGEMENT, L.P.DirectorMar 19Buy5.752,206,68512,688,43910,916,567Mar 23 04:30 PM
Schneider Joel Solomon ZevChief Operating OfficerMar 12Sale8.8423,398206,920268,774Mar 15 04:05 PM
Morris Carl AshleyChief Scientific OfficerMar 12Sale8.8423,398206,947275,602Mar 15 04:05 PM
Ganot IlanCEO & PresidentFeb 12Sale7.664573,5013,026Feb 16 04:00 PM
Morris Carl AshleyChief Scientific OfficerJan 28Sale6.143,45921,238299,000Jan 29 04:00 PM
Ganot IlanCEO & PresidentJan 28Sale6.1410,71365,7761,199,821Jan 29 04:00 PM
Ziolkowski Jennifer LynnCFO, Treasurer & Asst. SecyJan 28Sale6.143,47321,327335,636Jan 29 04:00 PM
Schneider Joel Solomon ZevChief Technology OfficerJan 28Sale6.143,44321,145292,172Jan 29 04:00 PM